Biotech/Pharmaceuticals
- Article Tools
- Email this Article
- Print this Article
- Rss Feed
- Related Articles
- Another Warning From Affymetrix
- Sigma-Aldrich in Oxford Biomedica Link
- Andrx Hopes to Pass FDA Review
- Del.icio.us
- Digg
- StumbleUpon
Cephalon (CEPH - Cramer's Take - Stockpickr) received conditional approval from regulators for Sparlon, a treatment for attention deficit hyperactivity disorder that has the same active ingredient as the company's Provigil. The Frazer, Pa., company got what's called an approvable letter from the Food and Drug Administration. Still, that doesn't allow Cephalon to start selling Sparlon just yet. The biopharmaceutical firm will have to meet some kind of additional requirement before it can receive full marketing clearance, but Cephalon didn't provide details about what conditions the FDA attached to the approval. Sparlon, which had been known as Attenace previously, is designed for ADHD in children and adolescents aged 6 through 17. The company said it was "working closely with the FDA to obtain final approval" for the drug. Cephalon expects to launch Sparlon in early 2006 if it gets the regulatory green light. Shares of Cephalon were gaining 98 cents, or 2.2%, to $45.26. Provigil is approved for adults with excessive sleepiness associated with narcolepsy, sleep apnea and a sleep disorder related to shift work.
10/20/05
Another Warning From Affymetrix
The company cuts its fourth-quarter product and product-related revenue forecast.
10/20/05
Sigma-Aldrich in Oxford Biomedica Link
The company will commercialize the gene therapy outfit's LentiVector product for research.
10/19/05
Andrx Hopes to Pass FDA Review
The company plans to meet with the agency next month to discuss its manufacturing issues.
08/05/08
Three Internet Stocks That Could Double
These forgotten Internet stocks are being accumulated by hedge funds.
08/15/08
The Five Dumbest Things on Wall Street
Raspberries for Apple; You'll be sorry, UBS; Fortress or Fort Knox? Wholly unappetizing Foods; give Liberty AOL or give them...
08/15/08
McCain Fund-Raising Picks Up
The GOP presidential candidate raised $27 million in July.
08/15/08
Cash-Back Cards Aren't Money in the Bank
Some credit and debit cards give you some cash back on purchases. But you need to manage it well to benefit from it.
More popular tickers are indicated by scale.
Sponsored by:
RSS
